---
filing: pass
consistency: pass
disclosure: pass
short: no_hit
third_party: n/a
block_final: false
blocking_issues: []
option_coverage: partial
---

# ELE — Adversarial review

**Date:** 2026-10-27
**Agent:** Milly
**Dive reviewed:** `ELE/research/deep_dive_2026-10-27.md`
**Valuation reviewed:** `ELE/research/valuation.json`
**Evidence:** `ELE/research/evidence/primary_financials_2026-10-27.json`

**Goal:** Truth-seeking QA. Not bearish for its own sake.

## Summary verdict

| Area | Status | One line |
| --- | --- | --- |
| Filing reconciliation | pass | 2025 cash, shares, and zero borrowings match the cited 40-F facts |
| Internal consistency | pass | Returns statement and classification use -4.55, the file's base |
| Disclosure scan | pass | Later 2026 exhibits are named as a gap, not as cash |
| Short activist scan | no_hit | No local short report reviewed |
| Third-party | n/a | Not in the base path |

**Overall:** No blocking factual error. The owner-cash path and the synthesis headline are distinguished.

## Filing reconciliation

| Claim in dive | Filing or file value | Match? | Severity |
| --- | --- | --- | --- |
| Royalty revenue $43.359 million | Evidence row, Form 40-F | yes | none |
| Operating cash $30.811 million | Evidence row | yes | none |
| Ending shares 63,829,995 | Evidence row | yes | none |
| Borrowings zero | Evidence row | yes | none |
| Base case -4.55% per year | valuation.json implied_return.base_pct | yes | none |
| Owner-cash path about -6.1% | results.base.return_pct | yes, and it is not the headline | none |

## Internal consistency

The executive summary, the returns statement, and the classification row all use -4.55. The -6.1 path is unbolded and labeled as the scenario result. Q2 2026 and the later portfolio purchase are not in the cash number. That omission is disclosed.

## [HUMAN REVIEW]

ISIN and CUSIP are still open. Do not treat -4.55 as a decision until a full year of the combined company is in the cash.
